Principle and Progress of Treating Lymphoma with CD22 as Immunotherapy Target
DOI:
https://doi.org/10.54097/hset.v36i.5733Keywords:
CD22, B-cell lymphoma, immunotherapy, ADC, CAR-T.Abstract
B-cell lymphoma is a type of lymphoid tissue tumour, which is usually caused by clonal proliferation of lymphocytes at different stages of differentiation. CD22 molecule is ubiquitous in normal B cells and B cell malignant tumours. It is a principal element in the B cell maturation and proliferation, and provides an important functional link to the adjustment of B cell surface and intracellular signaling and cell survival. Although the function of CD22 remains unclear, blocking the action of CD22 has been proved to inhibit the growth of malignant B cells and CD22 has become an important therapeutic target of B-cell lymphoma. We will also discuss the strategies for the treatment of B-cell lymphoma targeting CD22, including naked antibodies, bispecific antibodies, antibody-drug conjugate (ADC), antibodies conjugated to radioactive elements, and chimeric antigen receptor-based T-cell (CAR-T) cell immunotherapy.
Downloads
References
Rajewsky, K. Clonal selection and learning in the antibody system [J]. Nature, 1996, 381, 751–758.
Küppers, R., Klein, U., Hansmann, M.-L. & Rajewsky, K. Cellular origin of human B-cell lymphomas [J]. N. Engl. J. Med, 1999, 341, 1520–1529.
Stevenson, F. K. et al. The occurrence and significance of V gene mutations in B cell-derived human malignancy [J]. Adv. Cancer Res, 2001, 83, 81–116.
Moek, K.L.; de Groot, D.J.; de Vries, E.G., Fehrmann, R.S. The antibody-drug conjugate target landscape across a broad range of tumour types [J]. Ann. Oncol, 2017, 28, 3083–3091.
Tateno H, Li H, Schur MJ, Bovin N, Crocker PR, et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity [J]. Mol. Cell. Biol, 2007, 27: 5699–710.
Kawasaki N, Rademacher C, Paulson JC. CD22 regulates adaptive and innate immune responses of B cells [J]. J. Innate Immun, 2011, 3: 411–19.
Jellusova J, Wellmann U, Amann K, Winkler TH, Nitschke L. CD22 × Siglec-G double- deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity [J]. J. Immunol, 2010, 184: 3618–27
Yinhua Kang, Ming Fan. Anti-CD22 monoclonal antibody: Epratuzumab [J]. Progress in Pharmaceutical Science, 2009, 33, 3: 138-139
Nikesh N Shah, Lubomir Sokol. Targeting CD22 for the Treatment of B-Cell Malignancies [J]. Immunotargets Ther, 2021,10: 225-236.
Ilana R Yurkiewicz, Lori Muffly, Michaela Liedtke Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia [J]. Drug Des Devel Ther, 2018, 12: 2293-2300.
Kreitman, R. J., Squires, D. R., Stetler-Stevenson, M., Noel, P., et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies [J]. Journal of Clinical Oncology, 2005, 23(27), 6719-6729.
Loretta Sullivan-Chang, Robert T O'Donnell, Joseph M Tuscano. Targeting CD22 in B-cell malignancies: current status and clinical outlook [J]. BioDrugs, 2013, 27(4): 293-304.
John H Baird, Matthew J Frank, Juliana Craig. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma [J]. Blood, 2021, 137(17): 2321-2325.
Jay Y Spiegel, Shabnum Patel, Lori Muffly, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial [J]. Nat Med, 2021, 27(8): 1419-1431.
Schneider D, Xiong Y, Wu D, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models [J]. Sci Transl Med, 2021, 13(586): eabc6401.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
